Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67


PPARγ Promotes Growth and Invasion of Thyroid Cancer Cells.

Wood WM, Sharma V, Bauerle KT, Pike LA, Zhou Q, Fretwell DL, Schweppe RE, Haugen BR.

PPAR Res. 2011;2011:171765. doi: 10.1155/2011/171765. Epub 2011 Dec 12.


Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer.

Morrison JA, Pike LA, Sams SB, Sharma V, Zhou Q, Severson JJ, Tan AC, Wood WM, Haugen BR.

Mol Cancer. 2014 Mar 19;13:62. doi: 10.1186/1476-4598-13-62.


CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.

Min IM, Shevlin E, Vedvyas Y, Zaman M, Wyrwas B, Scognamiglio T, Moore MD, Wang W, Park S, Park S, Panjwani S, Gray KD, Tassler AB, Zarnegar R, Fahey TJ 3rd, Jin MM.

Clin Cancer Res. 2017 Oct 12. doi: 10.1158/1078-0432.CCR-17-2008. [Epub ahead of print]


Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo.

Zhang K, Yu M, Hao F, Dong A, Chen D.

Cancer Biomark. 2016 Sep 26;17(3):281-291.


Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.

Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP, Smallridge RC.

Oncogene. 2006 Apr 13;25(16):2304-17.


Aberrant l1 cell adhesion molecule affects tumor behavior and chemosensitivity in anaplastic thyroid carcinoma.

Kim KS, Min JK, Liang ZL, Lee K, Lee JU, Bae KH, Lee MH, Lee SE, Ryu MJ, Kim SJ, Kim YK, Choi MJ, Jo YS, Kim JM, Shong M.

Clin Cancer Res. 2012 Jun 1;18(11):3071-8. doi: 10.1158/1078-0432.CCR-11-2757. Epub 2012 Apr 3.


Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR.

Garg M, Kanojia D, Okamoto R, Jain S, Madan V, Chien W, Sampath A, Ding LW, Xuan M, Said JW, Doan NB, Liu LZ, Yang H, Gery S, Braunstein GD, Koeffler HP.

J Clin Endocrinol Metab. 2014 Jan;99(1):E62-72. doi: 10.1210/jc.2013-2994. Epub 2013 Dec 20.


The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer.

Chu R, van Hasselt A, Vlantis AC, Ng EK, Liu SY, Fan MD, Ng SK, Chan AB, Liu Z, Li XY, Chen GG.

Cancer. 2014 Jan 1;120(1):142-53. doi: 10.1002/cncr.28383. Epub 2013 Oct 2.


Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.

Wunderlich A, Fischer M, Schlosshauer T, Ramaswamy A, Greene BH, Brendel C, Doll D, Bartsch D, Hoffmann S.

Cancer Sci. 2011 Apr;102(4):762-8. doi: 10.1111/j.1349-7006.2011.01853.x. Epub 2011 Feb 17.


Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.

Marlow LA, Reynolds LA, Cleland AS, Cooper SJ, Gumz ML, Kurakata S, Fujiwara K, Zhang Y, Sebo T, Grant C, McIver B, Wadsworth JT, Radisky DC, Smallridge RC, Copland JA.

Cancer Res. 2009 Feb 15;69(4):1536-44. doi: 10.1158/0008-5472.CAN-08-3718. Epub 2009 Feb 10.


Expression of the ring ligase PRAJA2 in thyroid cancer.

Cantara S, D'Angeli F, Toti P, Lignitto L, Castagna MG, Capuano S, Prabhakar BS, Feliciello A, Pacini F.

J Clin Endocrinol Metab. 2012 Nov;97(11):4253-9. doi: 10.1210/jc.2012-2360. Epub 2012 Sep 4.


Error occurred: cannot get document summary



Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.

Xing M.

Thyroid. 2010 Jul;20(7):697-706. doi: 10.1089/thy.2010.1646. Review.


Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.

Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR.

Thyroid. 2009 Aug;19(8):825-35. doi: 10.1089/thy.2008.0362.


Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy.

Reddi HV, Driscoll CB, Madde P, Milosevic D, Hurley RM, McDonough SJ, Hallanger-Johnson J, McIver B, Eberhardt NL.

Cancer Gene Ther. 2013 May;20(5):267-75. doi: 10.1038/cgt.2013.16. Epub 2013 Apr 19.


FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma.

Bellelli R, Castellone MD, Garcia-Rostan G, Ugolini C, Nucera C, Sadow PM, Nappi TC, Salerno P, Cantisani MC, Basolo F, Gago TA, Salvatore G, Santoro M.

Endocr Relat Cancer. 2012 Sep 21;19(5):695-710. doi: 10.1530/ERC-12-0031. Print 2012 Oct.


Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma.

Guida T, Salvatore G, Faviana P, Giannini R, Garcia-Rostan G, Provitera L, Basolo F, Fusco A, Carlomagno F, Santoro M.

J Clin Endocrinol Metab. 2005 Aug;90(8):4703-9. Epub 2005 May 17.


Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.

Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN.

Clin Cancer Res. 2004 Dec 15;10(24):8594-602.


Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies.

Marlow LA, von Roemeling CA, Cooper SJ, Zhang Y, Rohl SD, Arora S, Gonzales IM, Azorsa DO, Reddi HV, Tun HW, Döppler HR, Storz P, Smallridge RC, Copland JA.

J Cell Sci. 2012 Sep 15;125(Pt 18):4253-63. doi: 10.1242/jcs.097428. Epub 2012 Jun 20.


Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.

Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A, Genua M, Vigneri R, Belfiore A.

Endocrinology. 2006 Sep;147(9):4463-75. Epub 2006 Jun 15.


Supplemental Content

Support Center